MMS SmartStart™ Tech-Enabled Solution Eases Document Content Creation Process
CANTON, Mich. (September 22, 2021) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced the release of SmartStart™ Tech-Enabled Templates to reduce time and effort in the document content creation process while increasing the quality of deliverables.
SmartStart™ Templates apply structured authoring rules to the authoring process and include tech-enabled templates for protocols, statistical analysis plans (SAPs), and clinical study reports (CSRs). These templates were developed to improve consistency, time-savings, and quality while allowing for the reuse of data across deliverables, such as protocol to protocol, protocol to CSR, protocol to SAP, CSR to CSR, and SAP to SAP.
Key features of SmartStart™ templates are proven to reduce human errors by:
- Automatically sharing reusable content within and across protocols, SAPs, and CSRs
- Reusable content in the body of the protocol and CSR will automatically update in the synopsis
- Reusable content can be imported between documents
- Increasing quality and reduction of authoring and QC effort
- Efficiently presenting reusable content across products, programs, and therapeutic areas
- Decreasing review times, allowing reviewers to focus on newly-added content
“A goal of the organization is to accelerate the development of new therapies,” said Audelia Munguia, Director of Safety Risk Management at MMS. “The innovative technology of our SmartStart™ templates will greatly reduce the time and effort needed when writing deliverables and bring therapies to patients quicker.”
Sponsors who use SmartStart™ Templates will experience increased consistency and efficiencies for internal teams, sites, regulators, investigational review boards (IRB), and patients, as well as in downstream documents as previously completed protocols can be transferred into SmartStart™ Templates.
Learn more about MMS technologies here.
About MMS Holdings
MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company was named Most Outstanding CRO in the 2019 Biotechnology Awards and Best Global CRO in the 2018 International Life Sciences Awards. For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.
Media Contact
Prasad Babu
media@mmsholdings.com
Suggested For You
news
December 8th, 2021
MMS Holdings Wins 2021 Scrip Award for Best Contract Research Organization
news
October 28th, 2021
Praxis bioresearch seeks support from MMS for Alzheimers Disease Therapeutics
news
October 28th, 2020
MMS Academy Launches Mobile App for Accessing Pharmaceutical Industry Virtual Learning Courses from Anywhere
news
August 18th, 2020
MMS Academy Partners with MPGI in India
news
October 10th, 2019
MMS Holdings Announces Status As A Finalist For Best Contract Research Organization
news
June 27th, 2019
MMS Holdings Launches New Time-Saving Application to Automatically Perform Quality Control and Style Checks for Medical Writers
news
March 13th, 2019
GHP Recognises MMS Holdings in the 2019 Biotechnology Awards Winners
news
August 23rd, 2018
MMS Wins Best Global Biotech CRO in the International Life Sciences Awards 2018
news
May 1st, 2018
MMS Partners with University of Findlay to Provide Medical Writing and Clinical Trial Disclosure Courses
news
November 15th, 2017
MMS Selected by Paratek to Support its NDA Submissions for Omadacycline
news
June 11th, 2014
MMS partners with Wayne State University to place Graduate Students in Scientific Summer Internship Program
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance